Drugs That Reduce Gastric Acid Flashcards
Stimulatory:
1. Histamine
2. Gastrin
3. Acetylcholine
Inhibitory:
1. PGE2
2. PGI2
3. Somatostatin
Histamine:
Released by..
Increased by …
Acts how
Released by enterochromaffin-like cells (ECL) Further increased by gastrin and acetylcholine
Histamine acts in a paracrine fashion on
parietal cell H2 receptors
Increasing intracellular cAMP Responsive to histamine concentrations below
threshold required for vascular H1
receptor activation
CLINICAL INDICATIONS FOR REDUCING ACID SECRETION
-Peptic ulceration (both duodenal and gastric)
* H. Pylori infxn
- GORD
* gastric acid damages oesophagus
- Zollinger- Ellison syndrome
* rare gastrin- producing tumor
- NSAIDS
* COX-2 inhibitors may offer an advantage by causing less GI-related adverse effects
THERAPEUTIC STRATEGIES
H2 receptor antagonists
Proton pump inhibitors
Antacids
Alginates
H. pylori eradication
Cytoprotective agents
HISTAMINE H2 RECEPTOR ANTAGONISTS
MoA
Major breakthrough in the treatment of gastric ulcers
Competitively inhibit histamine
actions at H2 receptors (reversible)
Inhibit histamine- and gastrin-
stimulated acid secretion
Decrease both basal and food-
stimulated acid secretion by 90% or more
. HISTAMINE H2 RECEPTOR ANTAGONISTS
, Beneficial Effects
Promote healing of gastric and duodenal ulcers
-Relapses likely to follow after cessation of treatment
Histamine receptor antagonists
Examples
Cimetidine, nizatidine, famoditine
Less effective than proton pump inhibitors (PPIs)
Adverse effects
Diarrhoea
Dizziness
Headache
Hypergastrinaemia
Cimetidine Adverse effects
Gynaecomastia in men and rarely, a decrease in sexual function
Probably caused by a modest affinity for androgen receptors
CYP450 inhibitor
Potentiates effects of a range of drugs e.g. oral anticoagulants and tricyclic antidepressants
Clinical uses for Histamine receptor antagonist
• Peptic ulcer disease: treatment
and prevention of gastric and
duodenal ulcers (including
NSAID-associated ulcers)
• GORD and dyspepsia
First line tx
Proton pump inhibitors
PROTON PUMP INHIBITORS
Prototypical drug + other examples
Prototypical drug: Omeprazole
Other PPIs
Esomeprazole
Lansoprazole
Pantoprazole
Rabeprazole
PPI MoA
—Irreversibly inhibits the proton pump
• Basal and stimulated gastric acid secretion are reduced
— Weak base
• Accumulates in the acid environment of the canaliculi of the stimulated parietal cell where it is activated
• Administration: 30 minutes before food
• Specific effect on parietal cells
Adverse effects are uncommon
- Headache
- Diarrhoea
- Rebound hypergastrinemia (problem when stopping tx)
- Hypomagnesemia
- Increased bone fracture risk
- Increased susceptibility to infections (e.g.
C difficile)
CLINICAL USES
Of PPI
• Peptic ulcer disease: treatment and
prevention of gastric and duodenal
ulcers (including NSAID-associated
ulcers)
• Treatment of GORD and dyspepsia
• As part of H. pylori triple/quadruple
eradication therapy
• Reduction of gastric acid secretion in
Zollinger-Ellison Syndrome